After reviewing studies and patient data, researchers found that people with Type 2 diabetes taking semaglutide may have about twice the risk of developing NAION compared to those not taking the drug
Semaglutide, the active ingredient in GLP-1 drugs, is protected in the U.S
Supplements: NAC, Alpha-Lipoic Acid, liposomal glutathione, and milk thistle may help maintain optimal levels
[3] Talenezhad N, Mohammadi M, Ramezani-Jolfaie N, Mozaffari-Khosravi H, Salehi-Abargouei A
GLP-1 medications approved to treat type 2 diabetes include: There was a follow-up period of 3 months to 2 years after the discontinuation of the use of GLP-1 medications
Patients should contact their healthcare provider if headaches persist beyond the first few weeks of treatment or worsen despite supportive measures